Journals / Gazi Medical Journal / 2009 / Cilt: 20 - Sayı: 2

Rezeke küçük hücreli dısı akciğer karsinomlu hastalarda nöroendokrin diferansiyasyonun önemi

The significance of neuroendocrine differentiation in patients with resected non-small cell lung carcinoma

Pages
64–71
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: NED may be of prognostic signifcance in patients with re- sected NSCLC but the clinical signifcance of NED in this subpopulationneeds further analysis with specifc antibodies in larger series.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Neuroendocrine differentiation (NED) can be detected in 10- 30% of non-small cell lung carcinomas (NSCLCs), with the highest fre- quency in adenocarcinomas (ACs) and large cell carcinomas (LCCs), byimmunohistochemical or electron microscopic techniques.
📊
Key Findings & Data:Materials and Methods: The relationship between NED and prognosiswas investigated by immunohistochemistry using neuron specifc enolase(NSE), chromogranin A (Chr A), and neuroflament (NF) in 71 patientswith surgically resected stage I-IV NSCLC.
💡
Conclusion & Impact:Conclusion: NED may be of prognostic signifcance in patients with re- sected NSCLC but the clinical signifcance of NED in this subpopulationneeds further analysis with specifc antibodies in larger series.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Neuroendocrine differentiation (NED) can be detected in 10- 30% of non-small cell lung carcinomas (NSCLCs), with the highest fre- quency in adenocarcinomas (ACs) and large cell carcinomas (LCCs), byimmunohistochemical or electron microscopic techniques. These tumorsare collectively referred to as non-small cell lung carcinomas with neu- roendocrine differentiation (NSCLC-NED). However, the clinical signif- cance of this feature is not fully elucidated in NSCLC-NED. The purposeof this study was to evaluate the prevalence and the clinical signifcance ofNED in patients with stage I-IV NSCLC by using immunohistochemistryfor neuroendocrine markers. Materials and Methods: The relationship between NED and prognosiswas investigated by immunohistochemistry using neuron specifc enolase(NSE), chromogranin A (Chr A), and neuroflament (NF) in 71 patientswith surgically resected stage I-IV NSCLC. The immunostaining resultsof NE markers were compared with survival data. Results: While NSE expression was detected most often in LCCs (66.7%),that of Chr A was seen mostly in ACs (25.8%) but none of the NSCLCcases showed immunoreactivity with NF. Multivariate analysis showedthat pneumonectomy versus lobectomy carried a poorer prognosis whileNSE expression predicted a better prognosis in NSCLC cases. Conclusion: NED may be of prognostic signifcance in patients with re- sected NSCLC but the clinical signifcance of NED in this subpopulationneeds further analysis with specifc antibodies in larger series.

Özet

Amaç: Nöroendokrin diferansiyasyon (NED) en sık adenokarsinomlar(AD’ler) ve büyük hücreli karsinomlar (BHK’ler) olmak üzere küçükhücreli dısı akciğer karsinomlarının (KHDAK’lerin) %10-30’unda im- münhistokimyasal veya elektron mikroskopik yöntemler ile saptanabilir.Bu tümörler kollektif olarak “nöroendokrin diferansiyasyon gösterenküçük hücreli dısı akciğer karsinomları (KHDAK-NED)” olarak isim- lendirilirler. Ancak bu özelliğin klinik olarak önemi KHDAK-NED’de tamolarak aydınlatılamamıstır. Bu çalısmada evre I-IV KHDAK’li hastalardanöroendokrin belirleyiciler için immünhistokimyasal yöntem kullanılarakNED’nin sıklığı ve klinik öneminin değerlendirilmesi amaçlanmıstır. Gereç ve Yöntem: Cerrahi olarak rezeke edilmis evre I-IV KHDAK’li71 hastada immünhistokimyasal olarak nöron spesifk enolaz (NSE), kro- mogranin A (Kr A) ve nöroflament (NF) kullanılmasıyla NED ve prog- noz arasındaki iliski arastırılmıstır. Nöroendokrin belirleyicilerin immün- boyanma sonuçları sağkalım verileri ile karsılastırılmıstır. Bulgular: NSE ekspresyonu en sık BHK’lerde (%66.7) saptanırken, Kr Aekspresyonu ise en sık AD’lerde (%25.8) gözlenmistir ancak NF ile hiç- bir KHDAK olgusunda immünreaktiviteye rastlanmamıstır. Multivary- ans analiz KHDAK olgularında; lobektomiye karsılık pnömomektomiuygulanmasının olumsuz, NSE ekspresyonunun ise olumlu prognostikfaktör olduğunu ortaya koymustur. Sonuç: Rezeke KHDAK hastalarında NED’nin prognostik bir önemiolabilir ancak daha genis olgu serileri üzerinde spesifk antikorlarlaçalısılarak, bu hasta popülasyonunda NED klinik açıdan daha ayrıntılıarastırılmayı gerektirmektedir.

🔖

Cite This Article

KAYI, A. C., BİRCAN, S., SERTÇELİK, A., PERÇİNEL, S. (2022). Rezeke küçük hücreli dısı akciğer karsinomlu hastalarda nöroendokrin diferansiyasyonun önemi. Gazi Medical Journal, Cilt: 20 - Sayı: 2, 64–71. https://ajindex.com/articles/520297

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer Press; 2004
  2. Brambilla E, Lantuejoul S, Sturm N. Divergent differentiation in neuroendocrine lung tumors. Semin Diagn Pathol 2000; 17: 138-148
  3. Naruke T, Tsuchiya R, Kondo H, et al. Implications of staging in lung cancer. Chest 1997; 112: 242S-248S
  4. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717
  5. Kardaun OJWF. Kidney-survival analysis of IgA nephropathy patients: A case study. In: Rao CR, Chakraborty R, eds. Handbook of statistics 8. Amsterdam: Elsevier Science Publishers BV.; 1991. p. 407-459
  6. Gazdar AF. Advances in the biology of lung cancer. Clinical signifcance of neuroendocrine differentiation. Chest 1989; 96: 39S-41S
  7. Gazdar AF. Advances in the biology of non-small cell lung cancer. Chest 1986; 89: 277-283
  8. Graziano SL, Mazid R, Newman N, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy in patients with nonsmall cell lung cancer. J Clin Oncol 1989; 7: 1398-1406
  9. Linnoila RI, Jensen S, Steinberg S, et al. Neuroendocrine differentiation in non-small lung cancer correlates with favorable response to chemotherapy. Proc Am Soc Clin Oncol 1989; 8: 248
  10. Berendsen HH, Leij L, Poppema S, et al. Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989; 7: 1614-1620
  11. Gazdar AF, Kadoyama C, Venzon D, et al. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr 1992; 13: 191-196
  12. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10: 209-219
  13. Shaw GL, Gazdar AF, Phelps R, et al. Correlation of in vitro drugsensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl 1996; 24: 173-185
  14. Schleusener JT, Tazelaar HD, Jung S, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer 1996; 77: 1284-1291
  15. Linnoila RI, Mulshine JL, Steinberg SM, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. A